semaglutide addiction treatment as a promising new for alcohol use disorder Researchers explore promise of GLP-1

This dual approach may lead to more effective appetite suppression and improved glucose metabolism compared to Ozempic, which targets only the GLP-1 receptor

Be mindful of sensitive or broken skin If your skin is irritated, inflamed, or damaged, it is better to pause usage until the skin barrier feels normal again

Gastrointestinal effects represent the most frequently reported adverse reactions, occurring in a substantial proportion of patients, particularly during treatment initiation and dose escalation: Nausea (very common, affecting more than 1 in 10 people) typically peaks during the first few weeks and often diminishes with continued treatment [1] [2] Diarrhoea (very common, affecting more than 1 in 10 people) Vomiting (common, affecting up to 1 in 10 people) Abdominal pain, constipation, and dyspepsia occur with variable frequency Reduced appetite is an expected pharmacological effect contributing to weight loss but may occasionally be excessive These gastrointestinal symptoms usually improve over time as the body adjusts to the medication

However, its best to introduce one at a time to monitor effects

Tirzepatide: The First Dual Agonist Tirzepatide is currently the only FDA-approved dual GIP/GLP-1 receptor agonist

Loren Pickart and is believed to play roles in tissue repair, inflammation control, and oxidative stress balance. Its levels decline with age, which is part of why its being studied for anti-aging and regenerative applications